Arpida Press Releases from 2007

PROGRESS OF PHASE I PROGRAMME WITH ORAL ICLAPRIM

“ROLLING” NDA FOR INTRAVENOUS ICLAPRIM IN cSSSI; ELECTRONIC SUBMISSION OF FIRST MODULES DUE BEFORE YEAR-END 2007

Reinach / Basel, Switzerland, 11 December 2007. Arpida Ltd (SWX: ARPN) announced today the enrolment and dosing of the first patients in the Phase II clinical study with intravenous iclaprim in the treatment of hospital-acquired pneumonia (HAP) / ventilator-associated pneumonia (VAP) / healthcare-associated pneumonia (HCAP). In addition, Arpida announced results of a Phase I study with oral iclaprim. The primary aim of the study was to assess the safety and tolerability of single ascending doses of an oral capsule formulation of iclaprim in healthy volunteers. Moreover, Arpida today announced that the first modules of the New Drug Application (NDA) for intravenous iclaprim in its first indication, cSSSI, are ready and will be filed before year-end 2007. The filing of the NDA package is expected to be completed by the end of February 2008.

Progress of ongoing programmes confirmed

Reinach / Basel, Switzerland, 2 November 2007. Arpida Ltd (SWX: ARPN) presents two clinical posters on its late-stage investigational antibiotic iclaprim at the 9th annual congress for Clinical Pharmacology (Verbund Klinische Pharmakologie – VKliPha) which takes place 1–3 November in Kiel, Germany. The posters presented at the conference further expand the substantial volume of data on iclaprim that is already available. At two recent conferences in the United States, Arpida has presented a total of 24 posters on iclaprim.

Reinach / Basel, Switzerland, 25 September 2007. Arpida Ltd (SWX: ARPN) had a significant presence at this year’s Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. ICAAC is a premier meeting for clinicians, researchers and scientists in the field of infectious diseases.

Reinach / Basel, Switzerland, 19 September 2007. Arpida Ltd (SWX: ARPN) presented a large body of preclinical and clinical data on its investigational drug iclaprim at the 47th annual Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in Chicago. ICAAC is a major scientific conference where thousands of scientists and clinicians from all over the world gather to discuss the latest developments in the field of infectious diseases.

• English
• German
• French

Phase III programme with intravenous iclaprim in its first indication completed

Regulatory filing expected before year-end 2007

• Iclaprim achieves pre-specified primary efficacy endpoint in its second Phase III trial
• Safety profile confirmed

Reinach / Basel, Switzerland, 15 July 2007. Arpida Ltd. (SWX: ARPN) today announced results from the second pivotal Phase III trial with intravenous iclaprim in patients with complicated skin and skin structure infections (cSSSI). In this trial, called ASSIST-2 (Arpida’s Skin and Skin Structure Infection STudies), iclaprim was compared to linezolid, marketed by Pfizer as Zyvox®. The pre-specified primary efficacy endpoint of statistical non-inferiority in the clinical cure rate at the Test-Of-Cure (TOC) visit was achieved, confirming the outcome of ASSIST-1. Moreover, iclaprim’s safety profile demonstrated in ASSIST-1 was confirmed in ASSIST-2.

THIS ANNOUNCEMENT IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION
IN OR INTO THE UNITED STATES, CANADA, AUSTRALIA OR JAPAN

Reinach / Basel, Switzerland, 22 March 2007. Arpida Ltd. (SWX: ARPN) today announced the completion of enrolment in ASSIST-2 (Arpida’s Skin and Skin Structure Infection STudies). This second Phase III trial completes the Phase III trial programme for Arpida’s lead antibiotic compound, iclaprim, in complicated skin and skin structure infections (cSSSI).

In vitro microbiology and proof of concept in topical models of infection

Reinach / Basel, Switzerland, 8 March 2007. Arpida Ltd. (SWX: ARPN) today announced positive results of in vitro microbiological studies with AR-2474 against a large panel of clinical isolates, including those resistant to various current therapies. In addition, topical applications of AR-2474 were found to be highly effective in eradicating methicillin resistant Staphylococcus aureus (MRSA) in preclinical models of skin infection and nasal carriage. AR-2474 is a novel antibiotic that is not affected by mechanisms of resistance to other antibiotics, e.g. mupirocin, fusidic acid, erythromycin and clindamycin.